23-25 April 2018
Boston, MA

Register by Friday, December 1 to save up to $500! 

Speakers

Expand/Collapse

Jeremy Caldwell
Executive Vice President & Chief Scientific Officer
Ardelyx

Jerry Colca
Executive & Vice President of Research & Development
Cirius Therapeutics

Jesper Gromada
Head of Metabolism, Obesity & Lipid Therapeutic Area
Regeneron Pharmaceuticals

Ji Zhang
Scientist
Merck

Jonathan Riek
Vice President, Musculoskeletal & Metabolic Imaging
BioTelemetry Research

Day One

Tuesday April 24, 2018

17.15 | Panel Discussion: Non-Invasive Biomarkers – How Near Are We?

Judith Ertle
Clinical Program Leader
Boehringer Ingelheim

Liangsu Wang
Vice President, Head of Biology
Morphic Therapeutics

Kendra Bence
Senior Director, Metabolism
Pfizer

Matthew Coghlan
Senior Director
Novo Nordisk

Michal Ayalon
Project Champion
Teva Pharmaceuticals

Michael Crackower
Executive Director, Immunology and Inflammation Discovery
Celgene

Day Two

Wednesday April 25, 2018

09.15 | Panel Discussion: Combinational Therapies in the Treatment of NASH

Michael Fuchs
Professor of Medicine
Virginia Commonwealth University

Nikolai Naoumov
Executive Director, Hepatology Science & Innovation
Novartis

Day Two

Wednesday April 25, 2018

09.15 | Panel Discussion: Combinational Therapies in the Treatment of NASH

08.15 | Targeting Multiple Pathways in NASH – Clinical Perspectives for Combination Therapies

Paul Grayson
President & Chief Executive Officer
Bird Rock Bio

Peter Traber
Director of The Board, President, Chief Executive Officer & Chief Medical Officer
Galectin Therapeutics

Day One

Tuesday April 24, 2018

17.15 | Panel Discussion: Non-Invasive Biomarkers – How Near Are We?

Day Two

Wednesday April 25, 2018

15.30 | Keynote: Clinical Trials & Endpoints in NASH Cirrhosis

Philip Hylemon
Professor of Microbiology & Medicine
Virginia Commonwealth University

Philip Just Larsen
Chief Scientific Officer, Senior Vice President, Global Head of Diabetes Research & Translational Science
Sanofi

Day Two

Wednesday April 25, 2018

16.00 | Keynote: Overview on NASH Heterogeneity & Relationships as a Sequel of CVM Disease

Puneet Arora
Senior Medical Director
Genentech

Ravi Ravinuthala
Director, Liver Clinic
Ohio GI

Ray Chung
Vice Chief of Gastrointestinal Division, Director of Hepatology & Liver Centre
Massachusetts General Hospital

Rebecca Taub
Found, Director & Chief Medical Officer, Executive Vice President, Research & Development
Madrigal Pharmaceuticals

Ryan Feaver
NASH Program Leader
HemoShear Therapeutics

Robert Walczak
Executive Vice President, Director of Research
Genfit

Day Two

Wednesday April 25, 2018

09.15 | Panel Discussion: Combinational Therapies in the Treatment of NASH

Saurabh Gupta
Director, Translational Research & Early Clinical
Takeda

Scott Q Siler
Chief Scientific Officer
DILIsym Services, Inc.

Sean Muthian
Executive Director, External Science Innovations
Allergan

Day Two

Wednesday April 25, 2018

09.15 | Panel Discussion: Combinational Therapies in the Treatment of NASH

Shirly Pinto
Head of Biology & Drug Discovery
Kallyope

Sophie Mégnien
Chief Medical Officer
Genfit

Day One

Tuesday April 24, 2018

08.45 | Exploring the Latest Regulatory Requirements for Developing NASH Therapeutics

Sudha Shankar
Head of Cardiometabolic Translational Medicine & Early Clinical Development
NGM Biopharmaceuticals

Day One

Tuesday April 24, 2018

17.15 | Panel Discussion: Non-Invasive Biomarkers – How Near Are We?

Thomas Hughes
President & Chief Scientific Officer
Zafgen

Thomas Murphy
Director, Scientific Applications
Organovo

Day One

Tuesday April 24, 2018

16.30 | Modelling Progressive Liver Disease Using 3D Bioprinted Human Liver Tissue

Ajit dash
Senior Safety Scientist
Genentech

Arie Regev
Chair, Liver & GI Safety Committee, Global Patient Safety
Eli Lilly & Company

Andy Nichols
Chief Scientific Officer
Catabasis Pharmaceuticals

Bart Staels
Chairman of the Scientific Advisory Board & Co-founder
Genfit

Bill Esler
Principal Scientist
Pfizer

Brian Wamhoff
Head of Innovation
HemoShear Therapeutics

Bryan Fuchs
Assistant Professor of Surgery
Harvard Medical School

Edgar Charles
Director, Exploratory Clinical & Translational Research
Bristol-Myers Squibb

David Lomb
Consultant
Defined Health

Dean Hum
Senior Executive Vice President & Chief Scientific Officer
Genfit

Day One

Tuesday April 24, 2018

16.45 | Identification of Biomarkers for the Diagnosis of NASH

Donna Cryer
President
Global Liver Institute

Gyongyi Szabo
Professor & Vice Chair of Medicine
University of Massachusetts Medical School

Hani Jouihan
Scientist, Cardiovascular & Metabolic Disease
MedImmune

James Swaney
Director of Biology
Inception Sciences

Jamie Bates
Research Scientist
Gilead Sciences

Jason Campagna
Senior Vice President, Global NASH Lead
Intercept Pharmaceuticals

Day One

Tuesday April 24, 2018

17.45 | Chair’s Closing Remarks

08.15 | Keynote: Review Latest Advancements in NASH Drug Development

08.00 | Chair’s Opening Remarks

Day Two

Wednesday April 25, 2018

16.30 | Chair’s Closing Remarks

08.00 | Chair’s Opening Remarks

Jasmohan Bajaj
Associate Professor, Division of Gastroenterology
Virginia Commonwealth University